introduction Multiple sclerosis (MS) is a chronic, immune-mediated, multifocal inflammatory disease of the central nervous system that attacks myelinated axons, producing variable destruction of myelin and axons and hence significant physical disability. (1) MS is the most common cause of severe neurological disability in young adults in the Western world (being usually diagnosed between 20 and 40 years of age), presenting with various and unpredictable symptoms that may include weakness, visual impairment, sensory problems, bowel and bladder incontinence, imbalance or pain in various parts of the body. The time course of the disease is uncertain. (2) In the recent decades there has been increasing interest in cognitive impairment and mood disorders in MS, as well as the physical disabilities associated with the disease. (3) Charcot was the first person to describe psychiatric symptoms in patients with MS in lectures at the Salpetriere hospital in the 19th century; Charcot described mania, hallucinations and depression alongside other signs of the disease. Depression is the most frequent psychiatric diagnosis in patients with MS and is an important source of morbidity and mortality. Lifetime prevalence of major depression ranges from 19 to 54%, three times higher than in the general population. Published data put the annual prevalence of depression at 16% and the prevalence of clinically significant depressive symptoms at 50%. Risk factors for major depression in MS include female gender, age less than 35 years, family history of major depression and stress. (4, 5) An investigation of the relationship between the frequency and severity of depression and the degree of functional disability suggested that patients with an elevated Expanded Disability Status Scale (EDSS) score were more likely to develop clinically significant depression. (6) Recent studies found that depression is frequently disregarded and undertreated in patients with MS; the diagnosis was missed in about 23-30% of the cases and inadequately treated in 20-36% of reported cases. (4) The degree of cognitive impairment is one of the most important determinants of quality of life of patients with MS. Neuropsychological studies suggest that 40-65% of Correspondence to: Rodica Bălașa E-mail: iipascu@redatronic.ro MS patients develop a cognitive impairment, impairments range from mild short-term memory deficits to severe impairments such as dementia. (7) Cognitive impairment may occur at any stage of the disease, including clinically isolated syndrome and early relapsing-remitting multiple sclerosis (RRMS). The areas of cognition most affected in MS patients are information processing speed, episodic memory and executive function. (8) The aim of this study was to evaluate depression and cognitive function in MS patients and calculate the correlations between measures of depression, cognitive status, functioning, disability and lesion load in MS. materials and methods Thirty-two RRMS patients treated with Interferon Beta 1a were included in the study. The inclusion criteria were: 1. male or female 18 -55 years old; 2. diagnosis of RRMS according to modified McDonald criteria 2010 with diseasemodifying therapies (DMT) indicated; 3. Patient is immunomodulator-naïve to drugs other than Interferon beta; 4. (female subjects only) practising effective contraception unless postmenopausal or surgically sterile; 5. able to comply with trial protocol; 6. able to undergo MRI. The exclusion criteria were: 1. treatment with corticosteroids within 30 days of testing. 2. participation in another non-MS trial within 3 months of the start date. 3. presence of a severe concomitant condition that is likely to affect participation in the study; 4. neuropsychiatric disorders unrelated to the MS; 5. physical impairment that could interfere with cognitive testing.
Depression level was evaluated using the Romanian version of Beck Depression Inventory (BDI); cognitive function with the Paced Auditory Serial Addition Test 3 (PA-SAT 3). Patients' functional status and disability level were evaluated with the Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS). All patients underwent cerebral MRI with a 1.5T MRI device, with intravenous administration of a contrast agent.
The BDI consists of 21 questions; responses are given on a four-point severity scale. A BDI score between 1 and 10 is considered normal, a score between 11 and 16 indicates mild mood disorder, 17 -20 indicates borderline depression, 21 -30 indicates mild depression, 31 -40 indicates severe depression and a score above 40 indicates extremely severe depression. (9) EDSS is a unified scale for the evaluation of functioning in MS patients; it assesses impairment in 8 functional systems. Total score on the EDSS can be between 0.0 (normal neurological status) to up to 10.0 (death). (10) The Symbol Digit Modalities Test (SDMT) was used to assess information processing speed. The test consists of single digits paired with abstract symbols. Rows of 9 symbols are arranged randomly, and the patient must say or write the number paired with the symbol displayed. The score was given by the total number of correct responses in 90 seconds (range 0-110). The SDMT is sensitive to cognitive decline and in clinical studies it has been shown to be one of the best predictors of secondary cognitive impairment in MS. (11) (12) The MSFC was used to evaluate three important clinical features of MS: leg function/ambulation (Timed 25-Foot Walk; T25-FW), hand function (9-Hole Peg Test; 9-HPT) and cognitive status (PASAT). Scores on each component are converted to standard scores. The T25-FW was the first MSFC component administered at each visit and provided a quantitative measure of leg function. The test requires the patient to walk 25 feet as quickly and safely as possible, following a clearly marked 25-foot course; the examiner measures and records the time taken. The test is performed twice. The 9-HPT is the second MSFC component administered. The 9-HPT is a quantitative measure of hand function; both the dominant and non-dominant hand were tested twice. (13) (14) The PASAT, the third MSFC component, was a measure of cognitive status based on tests of auditory information processing speed and calculation ability. The PASAT is presented on compact disc so that the rate of stimulus presentation can be controlled by the experimenter. One digit is presented every 3 minutes; the patient must add the new digit to the immediately preceding digit, and the score is the number of correct answers (maximum = 60). (13) (14) .
MRI examinations were performed with a 1.5 Tesla MRI device (GE Signa Excite II). The MRI protocol included the following sequences: T1-3D-FSPGR axial native+gadolinium, T2-SE axial, FLAIR axial, FLAIR sagittal, double inversion recovery (DIR) axial, magnetisation transfer imaging (MTI) axial and diffusion tensor imaging (DTI) axial.
statistical analysis
Differences between groups in terms of outcome variables were described using standard statistics, evaluated for significance using two-sample t-tests or Wilcoxon's rank-sum tests, depending on whether the distributional assumptions were satisfied judging by skewness-kurtosis tests.
Correlations between continuous variables were evaluated by calculating Pearson's or Spearman's coefficients depending on whether the linearity assumption was satisfied. Coefficients were estimated complete with 95% confidence intervals (based on Fisher's transformation) and p values, both for the whole sample and stratified for patient group.
Results
Demographic data for the patients are presented in Table I . Twenty-three patients showed no symptoms of depression (BDI score 1-10), 4 patients had mild mood disturbance (BDI score 11-16), 3 had borderline clinical depression (BDI score [17] [18] [19] [20] , and 2 had moderate depression (BDI score [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . The mean BDI score was 8.71±7. 16 . There was no statistically significant sex difference in BDI scores.
BDI score correlated significantly with scores on the EDSS (R=0.38, p=0.03); Figure 1 ), PASAT 3 (R=-0.42, p=0.01; Figure 2 ), SDMT (R=-0.58, p=0.0007; Figure 3 ), T25-FW (R=0.43, p=0.01; Figure 4 ) and 9-HPT (R=0.45, p=0.008; Figure 5 ).
EDSS functional scores correlated with the urinary score (R=0.4, p=0.01) and sensitive score (R=0.49, p=0.004).
The other components of EDSS functional scores were not correlated with BDI score.
BDI score correlated significantly with the total number of T2 lesions (R=0.31, p=0.05) ( Figure 6 ) but not with the number of active lesions.
BDI score was not correlated with patient age, duration of disease or number of relapses in the last year. discussion Evaluations of disability in MS place more emphasis on motor and ambulatory functions than on higher cortical functions; however, there is a wide range of neuropsychiatric comorbidities that significantly affect the quality of life of patients with MS (6, 15, 16) .
The relationship between depression and MS has long been recognised and investigated; most studies have reported high rates of depression in the MS population (15, 17, 18) .
A study conducted in Vancouver, which involved administration of a psychiatric interview to 221 patients with MS, revealed that 34.4% of patients had a lifetime diagnosis of depression and 50.3% of patients were estimated to be at risk for developing depression by age of 59 years [15, 19] . A Canadian study reported a 42% lifetime prevalence of clinically significant depression in patients with MS [15, 20] . Minden et al. concluded that 54% of MS patients [50] in their sample had met the diagnostic criteria for major depression at least once since their diagnosis; 14% of this subgroup had met the criteria prior to diagnosis [15, 21] .
Schiffer found that up to 65% of patients with MS reported depressive symptoms [15, 22] .
There have been few epidemiological studies of depression in MS. One population-based study examined 115,071 patients aged 18 years and older using the Composite International Diagnostic Interview Short Form for Major Depression. The one-year prevalence of major depression was 25.7% in the 322 participants with MS compared with only 8.9% in the general population [15, 21] .
Depression in MS may be more than a simple reaction to this debilitating disease; structural, psychoneuroimmunological and neurochemical abnormalities also play an important role. Understanding why depression is so frequent in MS patients is a complex and challenging task. The high incidence of depression in MS cannot simply be attributed to the burden of living with a disabling neurological disorder because there are other more severe neurological diseases, such as amyotrophic lateral sclerosis, in which depression is less frequent [15, 23] .
One might expect a linear relationship between depression and functional or physical disability in MS; however this has not been observed in all relevant studies. The reported lack of correlation between functional disability and depression suggests that the depression has other biological causes. The location of lesions in patients with MS and the degree to which limbic circuits are affected may represent a more important aetiological factor in depression in MS than physical impairment. One study found a significant correlation between depression and major cognitive decline and quality of life scores; surprisingly, depression was not correlated with neurological disability [15, 24, 25] . However, other authors found at least some correlation between physical functioning and depression in MS [15, 26] .
A study of 50 MS patients attending an outpatient clinic reported that BDI scores increased with disease severity and physical disability but not with disease duration (15, (27) (28) (29) (30) (31) In this study we found a significant correlation between depression and an objective measure of disability, the EDSS. Separate calculations of the correlation between depression and the 8 functional systems of the EDSS revealed that only bowel and bladder dysfunction and sensitive score were correlated with BDI score. Chwastiak et al. reported that the EDSS cognitive function score correlated more strongly with depression than other EDSS scores [6] . We did not replicate this finding. The EDSS cognitive function is based largely on self-report items; PASAT and SDMT scores provide more sensitive and objectives measures of cognitive functioning. We found a significant correlation between BDI score and functional impairment of the lower and upper extremities, assessed by T25-FW and 9-HPT respectively. This is the first report of a correlation between symptoms of depression and objective measures of physical disability.
Some studies suggest that depression is more common in women [15, 32, 33] , but the evidence on the relationships between age or gender and incidence of depression in patients with MS is inconsistent. Several studies found no significant gender-related difference in the incidence of depression [6, 15, 34] . Several community and tertiary centre studies have reported that older patients with MS report fewer symptoms of depression than younger patients [15, 30, 35] . We did not find any correlations between depression and patient age or gender.
The cognitive impairment is another factor that significantly influence life satisfaction and quality of life in MS; it is also the most important determinant of employment status and the social costs associated with MS [8, 36] . The prevalence of cognitive impairment in patients with MS is between 43-70%, cognitive impairment can occur at any stage of the disease and is only weakly correlated with disease duration and disability; some studies suggest that cognitive impairment is strongly associated with certain MRI parameters [8, [37] [38] [39] .
The current evidence for an association between cognitive impairment and depression is inconsistent, the association may be bidirectional [40] .
Several studies have found that patients with MS-related cognitive dysfunction report higher levels of depression than patients without cognitive impairment [24, 40, 41] . Other studies have failed to find an association between depression and cognitive impairment [42] .
Some studies have suggested that specific types of cognitive impairment may be preferentially related to depression, for example autobiographical memory deficits [43] . We found a significant correlation between BDI scores and scores on two tests known to be sensitive to cognitive impairment, PASAT, a combined measure of auditory information processing speed and calculation ability, and SDMT, a measure of information processing speed
There is little empirical evidence on relationship between lesion burden (assessed by MRI) and depression in MS. Feinstein et al. concluded that the burden of demyelinating lesions was associated with the severity of depression [44] ; we found that the level of depression correlated significantly with the number of T2 lesions on an MRI scan.
The main limitation of our study was the small size of the patient sample.
Conclusions
Our results suggest that there are significant correlations between depression and cognitive impairment, some important aspects of physical disability being assessed using an objective instrument and MRI parameters such as T2 lesion burden. The main determinants of depression in RRMS patients were cognitive impairment, the impairment in fine hand movements (9-HPT score), gait impairment (T25-FT) and bladder and sensitive dysfunction. The evidence for an association between these variables and depression remains confused and further research in this area is needed.
